Chi Yan

1.3k citations

43 papers · 805 indexed · h-index 18

Impact in

Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer-related Molecular Pathways
Immunology
- Immune cells in cancer
- Immunotherapy and Immune Responses

Papers in ⓘ

Oncology 23
- Cancer Immunotherapy and Biomarkers 13
- CAR-T cell therapy research 6
- Cytokine Signaling Pathways and Interactions 4
Health Informatics 1

Co-authors: Ann Richmond (14 shared papers)Genlou Sun (5 shared papers)Sheau‐Chiann Chen (11 shared papers)Jinming Yang (6 shared papers)Anna E. Vilgelm (7 shared papers)Gregory D. Ayers (5 shared papers)Christopher Andrew Johnson (3 shared papers)Nabil Saleh (6 shared papers)
Journals: Scientific Reports (3 papers)International Journal of Molecular Sciences (3 papers)Clinical Epigenetics (2 papers)Molecular Therapy — Oncolytics (2 papers)Molecular Phylogenetics and Evolution (2 papers)
Partner nations: United States China Canada

In The Last Decade

Chi Yan

40 papers receiving 798 citations

Peers

Countries citing papers authored by Chi Yan

Since Specialization

Citations

This map shows the geographic impact of Chi Yan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chi Yan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chi Yan more than expected).

Fields of papers citing papers by Chi Yan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chi Yan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chi Yan. The network helps show where Chi Yan may publish in the future.

Co-authors

The 25 scholars most cited alongside Chi Yan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Chi Yan Line = papers co-authored together Chi Yan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 43 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21 Science Translational Medicine ·Anna E. Vilgelm, Nabil Saleh, Rebecca L. Shattuck-Brandt, Kelsie Riemenschneider, Lauren Slesur, Sheau‐Chiann Chen, Christopher Andrew Johnson, Jinming Yang, Ashlyn Blevins, Chi Yan, Douglas B. Johnson, Rami N. Al‐Rohil, Ensar Halilovic, Rondi M. Kauffmann, Mark C. Kelley, Gregory D. Ayers, Ann Richmond	2019	88
2	Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy Clinical Epigenetics ·Takako I. Jones, Oliver D. King, Charis L. Himeda, Sachiko Homma, Jennifer C. J. Chen, Mary Lou Beermann, Chi Yan, Charles P. Emerson, Jeffrey B. Miller, Kathryn R. Wagner, Peter L. Jones	2015	59
3	Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity Cancer Immunology Research ·Jinming Yang, Chi Yan, Anna E. Vilgelm, Sheau‐Chiann Chen, Gregory D. Ayers, Christopher Andrew Johnson, Ann Richmond	2020	56
4	Identifying diagnostic DNA methylation profiles for facioscapulohumeral muscular dystrophy in blood and saliva using bisulfite sequencing Clinical Epigenetics ·Takako I. Jones, Chi Yan, Peter C. Sapp, Diane McKenna‐Yasek, Peter B. Kang, Colin Quinn, Johnny Salameh, Oliver D. King, Peter L. Jones	2014	54
5	Immunomodulatory Properties of PI3K/AKT/mTOR and MAPK/MEK/ERK Inhibition Augment Response to Immune Checkpoint Blockade in Melanoma and Triple-Negative Breast Cancer International Journal of Molecular Sciences ·Zhizhu Zhang, Ann Richmond, Chi Yan	2022	50
6	The lysosomal TRPML1 channel regulates triple negative breast cancer development by promoting mTORC1 and purinergic signaling pathways Cell Calcium ·Mengnan Xu, Shekoufeh Almasi, Yi Yang, Chi Yan, Andra M. Sterea, Alia Kazim Rizvi Syeda, Bing Shen, Derek R. Clements, Peng Huang, Shashi Gujar, Jun Wang, Wei‐Xing Zong, Mohamed Trebak, Yassine El Hiani, Xian‐Ping Dong	2019	49
7	Inhibition of the PI3K/mTOR Pathway in Breast Cancer to Enhance Response to Immune Checkpoint Inhibitors in Breast Cancer International Journal of Molecular Sciences ·Chi Yan, Jinming Yang, Nabil Saleh, Sheau‐Chiann Chen, Gregory D. Ayers, Vandana G. Abramson, Ingrid A. Mayer, Ann Richmond	2021	38
8	Hiding in the dark: pan-cancer characterization of expression and clinical relevance of CD40 to immune checkpoint blockade therapy Molecular Cancer ·Chi Yan, Ann Richmond	2021	34
9	A panel of DNA methylation biomarkers for detection and improving diagnostic efficiency of lung cancer Scientific Reports ·Bing Wei, Fengxin Wu, Wenqun Xing, Haibo Sun, Chi Yan, Chengzhi Zhao, Dongqing Wang, Xiaobing Chen, Yanli Chen, Mingming Li, Jie Ma	2021	34
10	Distinct Origin of the Y and St Genome in Elymus Species: Evidence from the Analysis of a Large Sample of St Genome Species Using Two Nuclear Genes PLoS ONE ·Chi Yan, Genlou Sun, Dongfa Sun	2011	32
11	Novel induction of CD40 expression by tumor cells with RAS/RAF/PI3K pathway inhibition augments response to checkpoint blockade Molecular Cancer ·Chi Yan, Nabil Saleh, Jinming Yang, Caroline A. Nebhan, Anna E. Vilgelm, E. Premkumar Reddy, Joseph T. Roland, Douglas B. Johnson, Sheau‐Chiann Chen, Rebecca L. Shattuck-Brandt, Gregory D. Ayers, Ann Richmond	2021	28
12	Myeloid-derived suppressor cell depletion therapy targets IL-17A-expressing mammary carcinomas Scientific Reports ·Bassel Dawod, Jinghua Liu, Simon Gebremeskel, Chi Yan, Antonia Sappong, Brent Johnston, David W. Hoskin, Jean S. Marshall, Jun Wang	2020	26
13	Harnessing the potential of CD40 agonism in cancer therapy Cytokine & Growth Factor Reviews ·Yang Zhou, Ann Richmond, Chi Yan	2023	26
14	Virotherapy-recruited PMN-MDSC infiltration of mesothelioma blocks antitumor CTL by IL-10-mediated dendritic cell suppression OncoImmunology ·Zhiwu Tan, Li Liu, Mei Sum Chiu, Ka‐Wai Cheung, Chi Yan, Zhe Yu, Boon Kiat Lee, Wan Liu, Kwan Man, Zhiwei Chen	2018	23
15	Metastatic Melanoma Patient–Derived Xenografts Respond to MDM2 Inhibition as a Single Agent or in Combination with BRAF/MEK Inhibition Clinical Cancer Research ·Rebecca L. Shattuck-Brandt, Sheau‐Chiann Chen, Emily Murray, Christopher Andrew Johnson, Holly Crandall, Jamye F. O’Neal, Rami N. Al‐Rohil, Caroline A. Nebhan, Vijaya Bharti, Kimberly B. Dahlman, Gregory D. Ayers, Chi Yan, Mark C. Kelley, Rondi M. Kauffmann, Mary Hooks, Ana M. Grau, Douglas B. Johnson, Anna E. Vilgelm, Ann Richmond	2020	22
16	Multiple origins of allopolyploid wheatgrass Elymus caninus revealed by RPB2, PepC and TrnD/T genes Molecular Phylogenetics and Evolution ·Chi Yan, Genlou Sun	2012	21
17	A prediction model based on DNA methylation biomarkers and radiological characteristics for identifying malignant from benign pulmonary nodules BMC Cancer ·Wenqun Xing, Haibo Sun, Chi Yan, Chengzhi Zhao, Dongqing Wang, Mingming Li, Jie Ma	2021	20
18	Eliminating mesothelioma by AAV-vectored, PD1-based vaccination in the tumor microenvironment Molecular Therapy — Oncolytics ·Zhiwu Tan, Mei Sum Chiu, Chi Yan, Kwan Man, Zhiwei Chen	2021	17
19	Combined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real‐world clinical example Molecular Oncology ·Bing Wei, Chengzhi Zhao, Jun Li, Jiuzhou Zhao, Pengfei Ren, Ke Yang, Chi Yan, Rui Sun, Jie Ma, Yongjun Guo	2019	15
20	IL‐17R deletion predicts high‐grade colorectal cancer and poor clinical outcomes International Journal of Cancer ·Chi Yan, Weei‐Yuan Huang, Jeanette E. Boudreau, Animamalar Mayavannan, Zhenyu Cheng, Jun Wang	2019	12

About Chi Yan

Chi Yan is a scholar working on Oncology, Health Informatics, Immunology, Cancer Research and Genetics, having authored 43 papers that have together received 805 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (13 papers), Immunotherapy and Immune Responses (7 papers), CAR-T cell therapy research (6 papers), Melanoma and MAPK Pathways (5 papers), Cytokine Signaling Pathways and Interactions (4 papers), Chromosomal and Genetic Variations (4 papers), Cancer Mechanisms and Therapy (3 papers) and RNA modifications and cancer (3 papers). The work is most often cited by research in Oncology (310 citations), Immunology (199 citations), Physiology (41 citations), Cancer Research (108 citations) and Molecular Biology (385 citations). Chi Yan has collaborated with scholars based in United States, China and Canada. Frequent co-authors include Ann Richmond, Genlou Sun, Sheau‐Chiann Chen, Jinming Yang, Anna E. Vilgelm, Gregory D. Ayers, Christopher Andrew Johnson, Nabil Saleh, Takako I. Jones and Peter L. Jones. Their work appears in journals such as Scientific Reports, International Journal of Molecular Sciences, Clinical Epigenetics, Molecular Therapy — Oncolytics and Molecular Phylogenetics and Evolution.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact